GDTC — CytoMed Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
HealthcareMicro Cap
- $26.06m
- $28.01m
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -0.851 | -1.94 | -2.05 | -3.13 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 0.029 | 0.678 | 0.375 | 1.23 |
Unusual Items | ||||
Equity in Net Earnings/Losses | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.01 | 0.116 | -0.366 | 0.112 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Payable / Accrued Expenses | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -0.635 | -0.849 | -1.71 | -1.4 |
Capital Expenditures | -1.17 | -0.265 | -0.582 | -0.474 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | 0 | -0.248 | -0.241 | 0 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Change in Net Investments | ||||
Purchase of Investments | ||||
Cash from Investing Activities | -1.17 | -0.513 | -0.824 | -0.473 |
Financing Cash Flow Items | -0.027 | -0.106 | 1.88 | -0.125 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 1.19 | 1.88 | 4.17 | 0.969 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -0.616 | 0.514 | 1.63 | -0.933 |